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Abstract 
Multiple sclerosis (MS) has experienced an explosion in therapeutic interventions over a relatively short period of time. Early diagnosis is 
therefore critical and diagnostic criteria continue to evolve. Patients without typical symptoms but with imaging abnormalities identical to those 
with MS (radiologically isolated syndrome) are now recognised. Clinical phenotypes now focus on the underlying clinical and imaging disease 
activity. Investigations into the genetic and environmental factors have disclosed part of the complex genetic architecture of the disease, and an 
increased risk of developing MS associated with low vitamin D levels, smoking and Epstein Barr virus infection. The adaptive and innate 
immune responses play a crucial role in the pathogenesis of MS. Magnetic resonance imaging is useful for monitoring treatment effect and 
safety, and has provided endpoints for clinical trials. The dozen or so treatments available for relapsing-remitting MS almost exclusively target 
the immune system and require a personalised medicine approach to maximise benefit. Treatment guidelines are now emerging. Treatment for 
the disabling, progressive phase remains limited, and a neuroprotective strategy, in combination with an immunotherapy, has the greatest 
potential to prevent progression. 
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Introduction 
Multiple sclerosis (MS) is a complex and poorly understood condition, where many of the fundamental questions relating to causation and 
susceptibility remain unanswered. It affects individuals in their early adult life, and has a huge impact functionally, financially and in terms of 
quality of life. Costs are considerable and rise steadily with increasing disability.1 
The last two decades have seen developments in our understanding and management of MS, but there are two facts that stand out above all 
others. The first is the explosion in the number of disease-modifying treatments (DMTs) available for relapsing-remitting MS (RRMS), in 
contrast to the paucity of effective treatments for the progressive forms of the condition, coupled with the lack of a major effect of DMTs on 
relapse-unrelated disability.2 
The second development is the greater focus on active management, with the patient at the centre. The emergence of effective treatments has 
created an impetus to diagnose as early as possible and encourage interventions at the earliest point in time.3 This is particularly apposite 
given the emerging evidence for activity prior to any overt clinical manifestations.4 These developments may have contributed to the improved 
longevity in MS,5 and improved rates of worsening and evolution to secondary-progressive MS (SPMS) when compared to earlier natural 
history cohorts.6 The plethora of new agents also poses challenges in selecting the right drug for the right person at the right time and the era of 
personalised medicine for MS has certainly come of age.7 Other key issues are the impact of age on the pathophysiology and clinical 
manifestations of the condition,8   and the adverse influence of co-morbidities on outcomes.9 
 
Epidemiology  
 
With a prevalence ranging from 50 to 300 per 100,000, it is estimated that there are approximately 2.3 million people with MS in the world 
today, though this is likely to be an underestimate given the relative lack of data in large populations notably in India and China (Figure 1).10 
MS is more commonly seen in women than in men, and there is accumulating evidence of increased incidence of MS, notwithstanding 
improved diagnostic techniques, particularly in women with relapsing-remitting onset.11 Most patients present in early adult life but in recent 
years there has been increased awareness of presentation in childhood.12 The majority of patients presenting in later life are progressive from 
onset, but this is not uniformly the case.13  
 
Although the global distribution of MS increases as one moves away from the equator,10 there are exceptions to this generalisation and, while 
MS is common in regions populated by people from northern Europe, this effect is modified by where these individuals live in early life.  
Migration studies going back 50 years14 indicate that migration from low risk to high risk regions in childhood is associated with a low risk and 
vice-versa. However the precise cut-off is less clear and it is likely that the risk of exposure spans a wider range than was initially thought.15  
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Aetiology 
 
Environmental, genetic and epigenetic factors play a causal role in MS and potentially interact with modifiable risk factors.16 Current 
discussions concern the identity of risk factors and the extent to which they contribute to MS aetiology. 
 
Environmental risk factors 
 
More recently, the role of risk factors such as sunlight, Vitamin D, diet, obesity in early life and cigarette smoking has received considerable 
attention.17 Chief amongst these are low Vitamin D levels and cigarette smoking, both of which are associated with and increased risk of 
developing MS.18–21 Therefore, correction of Vitamin D insufficiency could be important towards preventing MS, though there is no evidence of 
an association between neonatal Vitamin D levels and MS risk.22 The risk with cigarette smoking increases with duration and intensity and is 
stronger in men than in women. Obesity in early life is associated with a twofold increase in risk across men and women and may be due in 
part to lower Vitamin D levels in obese individuals. The long history of a potential association of MS with infection has moved to Epstein Barr 
virus, with evidence that infection as a young adult increases the risk of subsequently developing MS (relative risk 3.0).23  This is in keeping with 
the hygiene hypothesis postulates that multiple infectious exposures in early childhood, as is often the case in tropical and subtropical areas, 
whereas in temperate zones, these infections tend to be delayed until early adult life.24 
 
Genetics  
 
The increased heritability within families and the directly proportional decrease in risk with degree of relatedness argue that genetic factors play 
a prominent role.  
The human leukocyte antigen (HLA) region has been associated with hundreds of human diseases, including most autoimmune diseases.25 In 
MS, an association with the serotype DR2 (later known to be the gene DRB1*15:01) has been known since the 70’s26 and consistently 
replicated in multiple studies (Figure 2). The most recent estimates indicate that carriers of the HLA DRB1*15:01 allele are three times more 
likely to develop MS than non-carriers.27 More recent studies focused on the HLA region identified additional risk and protective alleles.27 Using 
the values of HLA allele sharing by descent in sibships, it has been estimated that the HLA locus accounts for 20–30% of the genetic 
susceptibility in MS.28  
With the introduction of high throughput genotyping technology and supported by world-wide collaborative efforts, genome-wide association 
studies (GWAS) allowed to identify genetic variants with minor effects including genes in IL2RA and IL7RA, the first two non-HLA 
associations.29 Subsequent GWAS and a meta-analysis identified another dozen associations including the regions of CD58, TYK2, STAT3, 
and TNFRSF1A.30 Altogether, the GWAS data seems to support the long-held view that MS susceptibility is conferred by the action of common 
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(i.e. those with a risk allele frequency of >5%) sequence allelic variants in multiple genes.31 These studies were extended over the last decade, 
and a new meta-analysis of all previous GWAS in MS, and its corresponding replication in a large cohort (>15,000 cases) has been recently 
conducted by the IMSGC; this work has now brought the total number of associations to more than 20032. These data provide the genetic 
architecture of MS, which suggest a key role of the immune system in MS.  
Genetics studies in MS have been largely successful in providing a large roster of common variants associated with susceptibility to this 
disease. The next generation of genetic studies will likely focus on the identification of determinants of disease progression and on how 
individual information can be used to personalize treatment and follow-up, in order to provide a more comprehensive and integrative care for 
MS patients.  
 
Immunology of MS  
Genetic and pathological studies point towards the adaptive immune system, which consists of T- and B-cells, as a key player in the 
pathogenesis of disease33,34. Inflammation in MS only affects the CNS strongly suggesting that T- and B-cell are selectively attracted by specific 
target antigens (probably autoantigens) that are only expressed in the CNS. Although several candidate antigens have been proposed, none 
has been confirmed35,36.  
Why immune responses are initiated against CNS antigens and maintained in MS is unclear. Generation of specific T-cell and B-cell 
responses, which involves the expansion of large numbers of antigen specific lymphocytes from few precursor cells in the lymph node, requires 
professional antigen presenting cells (APCs), such as dendritic cells. It is well established that autoreactive lymphocytes, which harbour the 
potential to induce CNS autoimmunity, are part of the normal lymphocyte repertoire. The pathogenic immune responses to CNS autoantigens 
might be initiated37 in two ways: (i) The CNS intrinsic model hypothesizes that the initial event takes place in the CNS, which leads to the 
release of CNS antigens to the periphery (either by drainage to the lymph nodes or active carriage by APCs). In the context of a 
proinflammatory environment, an autoimmune response is generated, which eventually targets the CNS (Figure 3). (ii) By contrast, the CNS 
extrinsic model hypothesizes that the initial event takes place outside of the CNS (e.g. in the context of a systemic infection) and leads to an 
aberrant immune response against the CNS (Figure 3). Several mechanisms (e.g., reactivity between microbial antigens and autoantigens or 
priming autoimmune responses by a strong inflammatory stimulus) may account for the initiation of autoimmune responses. Both scenarios will 
flow into a detrimental circle of events: tissue damage leads to release of antigens to the periphery, which primes new immune responses in the 
lymphoid tissue followed by the invasion of lymphocytes into the CNS (Figure 3). The sequence is quite compatible with the relapsing-remitting 
nature of diseases.  
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The innate immune system, mainly consisting of phagocytic cells, also seems to play an important role in the initiation and progression of MS. 
Macrophages promote the pro-inflammatory response of the T and B cells and execute tissue damage.  Early microglial activation may be one 
of the initial events in the development of MS lesions, and may be essential for intrinsic ignition mechanisms. When activated, microglial cells 
may contribute to MS pathology through a number of possible mechanisms, including secretion of pro-inflammatory cytokines, chemokines, 
free radicals and increased release of glutamate. 
During the progressive phase of disease the contribution of the peripheral immune system decreases and immune responses seem to be 
confined to the CNS compartment. CNS pathology changes from focal to diffuse white matter injury associated with microglia activation and 
diffuse lympho- and monocytic infiltrates38 and increasing cortical involvement, which has been reported by some to be associated with 
lymphoid like follicles in the meninges.39 This implies that the immune response is sequestered to the CNS compartment with little contribution 
from the periphery. It is, however, unclear whether diffuse tissue injury observed in progressive MS is caused by the compartmentalized 
immune response, involving both innate and adaptive immune cells, or a consequence of diffuse tissue injury caused by other mechanisms, 
including degeneration of chronically demyelinated axons,40 and damage or dysfunction of other glia cells,41,42 including microglia activation,43 
even in the absence of additional inflammatory damage, or the combination of both mechanisms.   
 
From the immune response to pathology 
 
Although it is unknown whether the mechanisms mediating the occurrence of MS lesions are qualitatively and/or quantitatively different 
between the white matter and grey matter, there may be processes that are “common” to the two compartments and link the different 
components of the innate and adaptive immune responses to MS pathology. The hallmarks of MS pathology are axonal or neuronal loss, 
demyelination, and astrocytic gliosis. Among these neuropathological characteristics, axonal (or neuronal) loss is particularly relevant because 
it is considered to be the main underlying mechanism of permanent clinical disability. Axonal loss may occur acutely in new inflammatory 
lesions, but also more slowly over time in the chronic demyelinated lesions. The exact mechanisms that lead to axonal loss are becoming to be 
understood, and some of them, such as the neuronal energy deficit, may occur in both the acute and chronic phases, while others, such as the 
loss of myelin trophic support which leads to progressive swelling and cytoskeletal disorganisation of chronically demyelinated axons, may be 
unique to the chronic phase. 
 
At the top of the cascade of events that lead to axonal loss (Figure 4) and link the activity of the inflammatory cells to the MS lesions, there 
may be the production of reactive-oxygen species (ROS) and nitric oxide (NO) from activated microglia and infiltrated macrophages.44 ROS and 
NO may induce neuronal mitochondrial dysfunction through several mechanisms; impaired mitochondrial activity, in turn, leads to further 
oxidative stress through increased ROS generation. Mitochondrial injury may contribute to all the pathological features that are typical of MS 
lesions, including demyelination, apoptosis of oligodendrocytes, and degeneration of axons (mainly of those with thin calibre)45. Specifically 
within axons, the reduced production of adenosine triphosphate (ATP) due to mitochondrial dysfunction may lead to increased calcium levels, 
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with consequent neuronal death (Figure 4).46 Recent evidence points towards mitochondrial DNA deletions in cortical neurons47, and iron 
accumulation within oligodendrocytes, as possible mechanisms that further enhance the neuronal oxidative stress induced by inflammation and 
mitochondrial dysfunction45.  
 
Pathogenic events, including inflammation, demyelination, axonal loss, and gliosis can be studied in vivo by using both conventional and 
advanced imaging techniques (Figure 4). As mentioned above, the consequences of the cascade of pathogenic events is neurodegeneration, 
which is captured in-vivo by reduced brain volume (or brain atrophy), measured by volumetric MRI; whole brain atrophy in MS occurs at rates of 
0.5-1.5%, and faster rates may be seen in the progressive phases of the disease and in the deep grey matter structures48. Despite the 
mismatch between the scale of the microscopic event and the resolution of the images, technical advances have led to the identification of 
structural, metabolic, and molecular imaging biomarkers49,50 that reflect underlying pathological changes, correlate with clinical changes and 
can be used in clinical trials to monitor the efficacy of treatments.  
 
 
From pathology to clinical features 
 
Early MS is usually characterised by acute episodes of neurological deficits (or relapses), which depend on both the location of the CNS region 
affected by the acute inflammatory demyelinating lesions and the extent of the inflammatory process. For example, the development of an 
acute inflammatory lesion in the optic nerve leads to optic neuritis, which is characterised by visual impairment and pain on eye movements. 
Optic neuritis will be therefore used in this section as a model to illustrate the mechanisms that link pathological abnormalities to clinical 
symptoms.  
 
Pro-inflammatory cytokines and NO in the optic nerve lesion, together with demyelination, are considered to be the major determinants of the 
(complete or intermittent) conduction block that is responsible for the visual loss, which is typical of optic neuritis.51 Demyelinated axons can 
become hyperexcitable and spontaneously generate impulses that translate into “positive” symptoms, such as the perception of flashing light or 
other phosphenes upon eye movements.  
 
Longitudinal studies carried out in patients following an episode of optic neuritis, have found that acute (and persistent) optic nerve 
demyelination is associated with increased vulnerability of axons and predicts the development of axonal loss after 6 months;52 these findings 
support the hypothesis that the lack of myelin-derived trophic support53 and mitochondrial dysfunction46 contribute to the degeneration of  
chronically demyelinated axons, responsible for irreversible disability in the progressive phase of the disease.45 Additionally, in progressive MS, 
pathology may shift from a “focal” pattern to a more extensive and diffuse pattern, affecting both the white and grey matter, and changes (either 
de- or increases) of functional connectivity have been observed.54,55 
 
 
Tissue repair, plasticity and clinical recovery  
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Clinical deficits caused by acute inflammatory demyelination may be reversible because of restoration of nerve conduction. The restored nerve 
conduction is more continuous (rather than saltatory) and is achieved because the demyelinated axonal membrane shows several changes 
following demyelination, including increase in sodium channels. In addition, remyelination leads to new myelinated internodes, which are, 
however, shorter and thinner than normal56. All these changes leads to increased energy demand (or increased ATP production), which, 
consequently, may induce changes in the size and number of mitochondria.46  
 
Particular attention has been paid to the spontaneous phenomenon of remyelination, which is overall sparse in chronically demyelinated MS 
lesions, despite the presence of axons and oligodendrocyte precursors in some of them.56 The main role of remyelination is to ensure axonal 
survival, rather than the restoration of nerve conduction.53 
 
In addition to these structural changes, the recovery of clinical symptoms may also be secondary to cortical plasticity,57 which consists of a 
reorganisation of the functional activation of cortical regions aimed to maintain clinical function. In the case of optic neuritis, early neuroplasticity 
in higher visual areas appears to be an important determinant of recovery, independent of tissue damage in the anterior or posterior visual 
pathway.58 Neuroplasticity at the synaptic level has been explored and long-term potentiation of synaptic transmission may functionally 
compensate for neuronal loss.59 
  
Diagnosis 
The increasing acceptance that early intervention is important in the treatment of MS together with the growing awareness of the need to 
personalise treatment so that it aptly addresses the level and extent of disease activity have together emphasised the importance of early and 
accurate diagnosis and meaningful description of the disease course.  
The diagnosis of MS remains fundamentally clinical and requires the necessary clinical expertise to demonstrate evidence of dissemination in 
time (DIT) and space (DIS) and, importantly, the exclusion of other neurological conditions. The incorporation of MRI can provide this evidence 
and assists in excluding other conditions. MRI has added accuracy and allowed earlier diagnosis with greater certainty. The criteria have 
evolved as technology has improved, to refine definitions, become simpler, more accessible and applicable to a larger proportion of the 
population while maintaining specificity and sensitivity.60,61 The latest revision continues this trend while re-instating the role of abnormalities of 
the CSF.61 All changes were evidence-based and arrived at by consensus (Table 1). Inevitably these criteria will continue to evolve, particularly 
as MRI becomes increasingly more sophisticated.  Standardized protocols for the evaluation of patients with suspected or clinically definite MS 
have been suggested for baseline and follow-up scans and for brain and spinal cord imaging62.  
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The diagnostic criteria should be applied to diagnose patients who present with symptoms typical of MS and in whom MS is suspected, and not 
to differentiate MS from other neurological disorders. Inappropriate application of diagnostic criteria to patients with symptoms atypical for 
demyelination was the main contributor to MS misdiagnosis.63 A combination of MRI, serological and genetic testing, in association with clinical 
features and history, should be taken into account to navigate through the differential diagnosis of idiopathic inflammatory disorders, including 
neuromyelitis optica spectrum disorder (NMOSD),64 and other relapsing disorders that can mimic MS (Table 2). 
Phenotype  
The overwhelming majority of those developing MS begin with a single episode, clinically isolated syndromes (CIS) (Figure 5 (A)), involving the 
optic nerve, brainstem and spinal cord, which resolves over time. The concept of CIS is now well established65 and is being incorporated into 
the WHO-ICD 11. CIS patients subsequently have a further episode (relapse) and are described as having RRMS. About one third of this 
population will develop progressive disability with or without superimposed relapses and are then described as having secondary-progressive 
MS (SPMS)66.  This proportion, though, will likely continue to evolve as we gain more insights to the impact of DMTs on the natural history of 
the disease. In contrast about 15% of patients have a slowly progressive onset (PPMS)67. More recently, there has been a focus on the earliest 
stages of the condition. Patients with incidental MRI findings consistent with MS, the so-called ‘radiologically isolated syndrome’ (RIS) (Figure 5 
(A)),68 has been described and indicators for those more likely to demonstrate clinical symptoms of MS and further MR abnormalities over time 
are emerging.69 Evolution of patients with RIS into RRMS and PPMS has recently been demonstrated70. Finally, there has been further 
exploration of the two forms of progressive multiple sclerosis and an appreciation that they are more similar than different, i.e. the differences 
between them are relative rather than absolute.71 
While we have become accustomed to this terminology, as advocated by Lublin and Reingold over 20 years ago72 it is clear that they are purely 
descriptive and don’t provide information about the underlying pathophysiology. The recent phenotype paper, has begun to address this by 
advocating a focus on the presence or absence of activity, whether clinical or imaging, and addressing the two key components: relapses and 
progression and, on MRI, new lesions indicating inflammatory activity and atrophy indicating progression73 (Figure 5 (B)).  
Predicting clinical course  
Efforts have been made to identify clinical and radiological features that predict the clinical course of the disease. Thirty-four percent of patients 
with RIS develop a first acute clinical event consistent with CIS/MS within 5 years follow-up;74 risk factors for developing a first symptomatic 
event include male sex, younger age at the time of RIS diagnosis (<37 years), and presence of spinal cord lesions.74 Spinal cord lesions and 
male sex predicted evolution of RIS to PPMS, which has a prevalence of 12% in a large, multicentre cohort.70 In patients with CIS, the 
demographic (female sex and younger age) and topographic characteristics (non-optic neuritis presentations) are low-impact prognostic 
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factors, the presence of oligoclonal bands is a medium-impact prognostic factor, and the presence of 10 or more brain lesions on brain MRI is a 
high-impact prognostic factor for conversion to clinically definite MS and disability.75 In addition to baseline lesion number, the increase in lesion 
volume during the first 5 years is associated with higher disability after 20 years.76 In patients with CIS and non-spinal presentation, the 
presence of spinal cord lesions predicts a second clinical event.77 Receiving DMT prior to the second attack is associated with a lower risk of 
reaching moderate disability.75 DMT exposure is the most protective factor against disability-worsening events in paediatric CIS.78 Clinical 
outcomes, including disease activity and neuropsychological tests, suggest a persistent, long-term benefit of an early treatment at onset of 
CIS.79 In patients with CIS on DMT vitamin D levels predict disease activity and prognosis.19 Once MS diagnosis is confirmed, older age, male 
sex, higher disability at baseline, and greater brain atrophy (mainly in the deep grey matter nuclei) are predictors of disability accumulation.48,80 
Because of several, technical issues relating to MRI techniques and methodology, brain atrophy cannot yet be recommended in clinical practice 
for prognosis (or diagnosis)62. Females have a higher relapse rate than males throughout the course of MS.81 Overall, an active management of 
MS with DMTs is associated with a favourable clinical outcome, reflected by 11.3% of MS patients transitioning to SPMS during 10-year follow-
up6. In patients with MS on DMT, the presence of on-therapy relapses is associated with poor-prognosis.82 
Treatment 
Disease modifying-treatments (DMTs) 
Over the last ten years several DMTs have been discovered and approved for patients with RRMS (Figure 6). In general, these DMTs target 
neuroinflammation, and are considered to have a marginal, if any, effect on neurodegeneration, which is the main underlying mechanism of 
progression of disability in MS. The efficacy of DMTs on reducing the development of brain atrophy in clinical trials has been moderate at best 
(Table 3). At present, only one DMT (ocrelizumab) is approved by regulatory authorities in the United States, Australia and Switzerland (but not 
by the European Medical Agency) to slow down or stop progression in patients with progressive MS. 
Although the comparison between the effectiveness of DMTs relies on meta-analysis,83 and observational cohorts studies84 because of the lack 
of head-to-head trials, the recently licensed DMTs are more effective in reducing the relapse rate than older DMTs (Table 3). The higher 
efficacy of newer medications has introduced the concept of “no evidence of disease activity” (NEDA) into clinical trials; this is defined by the 
absence of relapses, disability progression, and active MRI lesions (both new or enlarged T2 lesions and gadolinium-enhanced lesions)85 If 
DMTs are prescribed at an early stage of the disease, and brain MRI is repeated annually in patients with RRMS, as recommended,73 NEDA 
could become a target in the clinical practice. Guidelines on the MRI protocols for monitoring of patients in clinical practice have recommended 
the use of T2-weighted and contrast-enhanced T1-weighted brain MRI, which reveal (subclinical) acute and active inflammation; spinal cord 
imaging, brain volume measures, and advanced MRI methods, although useful to understand the course of MS, are not recommended for 
routine monitoring86.  
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The high number of DMTs available has made the management of patients more complex. Two therapeutic approaches are available in the 
clinical setting. The first is termed “escalation” strategy. It consists of starting with a first line DMT, and then escalating to a more effective 
medication, if the patient’s relapse rate has not changed when compared with the pre-treatment period. Although this is a sensible approach, 
the timing and nature of the escalation from less effective medications to more effective treatments can be challenging in terms of treatment 
choice. In an attempt to help choosing the next drug, recent registry data have demonstrated that the relapse rate was 50% lower after 
switching from injectable DMTs to natalizumab than fingolimod, but none of these drugs had a significant impact on disability progression.87 
Additionally, the escalation strategy may not work for patients who have a highly active or rapidly evolving disease. For these cases, the 
“induction” strategy may be more appropriate. It consists of starting with a very effective medication, such as alemtuzumab or ocrelizumab, 
which is followed by a permanent disease remission or a long-term maintenance treatment with a less effective DMT, if needed.88 The choice 
between these two strategies should be ideally made on the basis of prognostic biomarkers that identify patients who are more likely to benefit 
from a specific treatment plan.  
The most effective medications for MS have the highest risk of serious adverse events. Alemtuzumab has been associated with severe 
autoimmunity related adverse events and infections (e.g., Listeria); natalizumab and, more recently, other DMTs,89,90 have been associated with 
progressive multifocal leukoencephalopaty (PML), caused by the reactivation of the JC virus. An estimation of the risk of PML in patients on 
natalizumab is obtained on the basis of the anti-JC virus antibodies status, prior use of immunosuppressants, and duration of natalizumab 
treatment.91 The quantification of anti-JCV antibodies levels has been introduced in the risk assessment routinely performed in the clinical 
practice.92 However, patients with negative anti-JCV antibody are still at risk of PML either because of a de-novo infection, or because of false 
negative test results, or because of a too low peripheral viral activity that does not reach the threshold.93 This urges clinicians to remain alert 
and consider the possibility of PML even when treating JCV-seronegative patients. Repeated MRI scans help the differential diagnosis between 
PML and MS-related lesions, and allow detection of asymptomatic cases of PML, who are associated with a more favourable prognosis.94  
New data on the safety and efficacy of CD20 depleting monoclonal antibodies, such as rituximab, ocrelizumab, and ofatumumab95, are 
encouraging. The last agent and ocrelizumab are anti-CD20 monoclonal antibodies. Long-term experience of safety and patient convenience of 
the anti-CD20 therapy is provided by rituximab, which has been used to treat rheumatoid arthritis and hematologic malignancies; rituximab has 
been demonstrated to have an effect on inflammatory MRI lesions and clinical relapses in RRMS and in a subgroup of patients with PPMS.96 
The efficacy of ocrelizumab, an mAb targeting the same CD20 epitope than rituximab, was recently demonstrated in phase III trials in RRMS 
and PPMS97,98. However, treatment with monoclonal antibodies may be a unique, predisposing factor for the development of PML (for example, 
PML has been observed with rituximab). The effects of these antibodies on the immune system that may predispose to PML has to be fully 
understood in order to develop strategies for prevention and treatment of PML. Additionally, novel DMTs have an unknown long-term safety 
profile.  
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The last medication approved by the European regulatory agency for the treatment of highly active MS is cladribine. Clinical trials with 
cladribine have provided evidence of its efficacy in delaying conversion from a first clinical demyelinating event to clinically definite MS99,100 and 
in reducing relapse rates, the risk of disability progression, and MRI measures of disease activity in RRMS101. A recent meta-analysis has 
supported an increased cancer risk of cladribine when compared with other treatments102 . 
The first steps towards the treatment of progressive MS have been made over the last decade. A phase II trial in secondary progressive MS 
has shown that simvastatin reduces progression of annualised brain atrophy by 43% over 2 years,103 and a phase III trial with this medication is 
currently ongoing. The effect of simvastatin on brain atrophy, the preliminary findings of recent trials with biotin104 and ocrelizumab,98 the current 
treatment trial with laquinimod in primary progressive MS to define its optimal dose and indication, and the impressive effort and commitment of 
the international Progressive MS Alliance,105 represent a good auspice for the approval of the first treatment for progressive MS in the near 
future.  
After the halt of disease activity and progression, there is the aspiration to obtain an improvement in clinical disability. A sustained remission of 
active MS and improvements in neurological disability were reported in RRMS patients who failed to respond to DMTs and received a high-
dose immunosuppressive therapy and autologous hemapoietic cell stem transplantation (aHSCT).106 Patients most likely to benefit from aHSCT 
are relatively young (50 years of age or less), with relatively short disease duration (5 years or less), have active RRMS, are accumulating 
disability but still are able to walk, and have ongoing relapses and MRI activity despite DMT.107 Longer follow-ups and head-to-head 
comparisons between aHSCT and the most effective DMTs are necessary to understand how to position aHSCT for the management of MS 
patients with the most aggressive disease.  
While the dramatic increase in the number of approved DMTs is welcome, inequalities across countries in the DMTs costs has become 
apparent;108 additionally, the introduction of newer DMTs has tended to raise the costs of older DMTs, which are matching the prices of the new 
competitors, at an unacceptable and potentially unsustainable rate.108 The availability of DMTs tends to be higher in high-income countries than 
medium-low income countries,10 and the accessibility to medications is not homogeneous even in countries where DMTs are available through 
government-funded schemes.10 The introduction of generic drugs that have equivalent efficacy, safety, and tolerability as the brand DMTs109 
may lead to less-expensive MS therapies.110 
Treatment of acute relapses 
The major focus of research over the last decade has been to assess whether oral steroids have the same effect as intra-venous (IV) steroids 
to treat acute relapses. The 2012 Cochrane review that performed a meta-analysis of the previous five randomised trials that compared oral 
and intravenous steroids for the treatment of relapses concluded that there were no significant differences in clinical and MRI outcomes 
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between oral and intravenous administration, but larger trials, with greater statistical power, were needed.111 The landmark study is a 
multicentre, double-blind, randomised, controlled, non-inferiority trial which has been recently published112; it compared oral vs. intravenous 
methylprednisolone, 1000 mg, once a day for 3 days and found that the oral treatment was not inferior to the IV one. The patient characteristics 
were a mix of visual, pyramidal, sensory, cerebellar and brainstem relapses and both treatment groups had similar relapse rate over the 
subsequent six months. These findings may allow more patients to have access to steroids more rapidly, and in a more comfortable way, and 
reduce the cost of the management of MS relapses. 
Management 
Active management, centring on the person with MS, is advocated at all stages of the condition to minimise disease impact, maximise quality of 
life and espouse a philosophy of wellness.113 Exercise is now playing a central role following a number of positive studies in mobility across  
relapsing/remitting and progressive MS.114,115  Effects on cognition are now being explored116. However the evidence base remains limited,117 
mechanisms are not well understood and translation into clinical practice is poor.118 Prevention of falls, a frequent occurrence in MS, associated 
with continence issues, previous falls and medication is another key element of good management.119 Multidisciplinary, goal-orientated 
rehabilitation incorporates all these elements but again methodologically sound studies are few120 and, as a consequence, the evidence base is 
relatively poor with few level 1 recommendations.121 More studies on modifiable risk factors, including lifestyle and Vitamin D, known to worsen 
the condition are also required117.  
Addressing the array of symptoms that are seen in MS is a critical component of management (Table 4). While drug treatments are available 
for some symptoms, the evidence base is poor and well-designed trials with adequate numbers are the exception, though studies of fampridine 
provide a useful model going forward.122  Many symptoms, such as spasticity, require a multi -disciplinary approach and the careful selection of 
treatments appropriate to the severity of the symptom. Overall it requires a sound knowledge base and a continuing treatment plan. The value 
of rehabilitation in cognitive dysfunction is now better appreciated.123,124 This is coupled with a better understanding of underlying mechanisms 
relating to connectivity125 and more innovative approaches to treatment.126 
Future  
 
The therapeutic developments seen in MS are unequalled in any area of neurology and the challenge now is to get the greatest benefit from 
the available armamentarium and ensure equity of access globally. The greatest outstanding challenges are to clarify mechanisms and improve 
trial outcomes, which will facilitate the development of much needed treatments for progressive MS. It is expected that reparative agents will be 
used in combination with existing immunotherapies to prevent clinical progression. Advances in symptomatic management and rehabilitation 
across the entire spectrum of MS are needed. 
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Search strategy and selection criteria 
Resource publications for this seminar were identified through searches  of PubMed and MEDLINE, and references from selected articles, 
using search terms relevant to each section of the Seminar, and a filter for publication date (up to September 2017).      Studies chosen for this 
Seminar describe the most recent advances in research, were published in high-impact, peer-reviewed journals, and showed results based on 
satisfactory numbers of study participants, covering a relevant population.  Only articles in English were chosen.   
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Table 1: The 2017 McDonald Criteria for diagnosis of multiple sclerosis in patients with an attacka at onset 
CLINICAL PRESENTATION ADDITIONAL DATA NEEDED FOR 
MS DIAGNOSIS 
≥2 clinical attacks and objective clinical evidence of ≥2 lesions; or ≥2 clinical attacks and objective 
clinical evidence of 1 lesion and clear-cut historical evidence of a prior attack involving a lesion in a 
distinct anatomic locationb 
Nonec 
 
≥2 clinical attacks; and objective clinical evidence of 1 lesion Dissemination in space, 
demonstrated by: 
A second clinical attack implicating a 
different CNS site 
OR 
Demonstration of DIS by MRId 
1 clinical attack; and objective clinical evidence of 2 or more lesions Dissemination in time, demonstrated 
by: 
A second clinical attack 
OR 
Demonstration of DIT by MRIe 
OR 
Demonstration of CSF-specific 
OCBsf 
1 clinical attack; and objective clinical evidence of 1 lesion Dissemination in space and time, 
demonstrated by: 
16 
 
For DIS: 
A second clinical attack implicating a 
different CNS site 
OR 
Demonstration of DIS by MRId 
 
AND 
 
For DIT: 
A second clinical attack 
OR 
Demonstration of DIT by MRIe 
OR 
Demonstration of CSF-specific 
OCBsf 
 
If the 2017 McDonald Criteria are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is MS. If MS is suspected 
by virtue of a CIS but the 2017 McDonald Criteria are not completely met, the diagnosis is “possible MS.” If another diagnosis arises during the 
evaluation that better explains the clinical presentation, the diagnosis is “not MS.” (From Thompson et al, Lancet Neurol 201761, Permission to 
reproduce obtained). 
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Table 2. Differential diagnosis of MS: clinical, MRI and serological findings of the main disorders that can resemble RRMS 
 Typical neurological features Typical MRI features Typical blood tests and 
CSF findings 
Neuromyelitis optica 
spectrum disorder 
Concomitant or concurrent 
(severe) optic neuritis and 
transverse myelitis; nausea and 
vomit; paroxysmal tonic spasms 
Longitudinally extensive spinal cord lesion 
(>3 vertebral segments); optic chiasmal 
involvement; pencil-thin ependymal 
enhancement and cloud-like enhancement 
Serum autoantibody to 
aquaporin-4 (AQP4-Ab) and 
to myelin oligodendrocyte 
glycoprotein (MOG-Ab) 
Neurosarcoidosis Cranial nerves involvement (in 
particular facial and optic nerve 
involvement); headache; raised 
intracranial pressure; meningitis; 
seizures; myelopathy 
Meningeal enhancement with pituitary, 
hypothalamic and cranial nerves 
involvement; brain white matter lesions; 
simultaneous enhancement of all lesions  
Raised serum and CSF 
ACE  
Neuro-Behçet’s disease Brainstem syndrome; myelopathy; 
meningoencephalitis 
Large brainstem lesions; basal ganglia, 
subcortical white matter and spinal cord 
lesions; gadolinium enhancement; cebral 
venous sinus thrombosis 
HLA-B5; CSF pleocytosis 
Connective tissue disorders 
(systemic lupus 
erythematosus (SLE), 
Sjögren syndrome, 
antiphospholipid antibodies 
syndrome) 
Optic nerve, brain and spinal cord 
involvement; neuropsychiatric 
symptoms; seizures; ischaemic 
episodes 
Brain infarcts and hemorrhage; basal 
ganglia lesions; punctuate (subcortical) 
lesions; spinal cord lesions; cebreal 
venous sinus thrombosis; parotid gland 
involvement in Sjögren 
Serum antinuclear antibody 
(ANA); ENA (in particular, 
anti SS-A(Ro) and SS-B(La) 
antibodies for Sjögren, and 
anti-Sm for SLE) 
Central nervous system 
vasculitis 
Confusion, headache, personality 
change; seizures; stroke-like 
Ischemic, multiple lesions; predominance 
of lesions at the cortico-subcortical 
junction; intracranial haemorrhage; 
Serum anti-neutrophil 
cytoplasmic antibodies 
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symptoms; meningeal enhancement; simultaneous 
enhancement of all lesions; microbleeds 
(ANCA) 
Hypoxic-ischaemic 
vasculopathies (in 
particular: small vessel 
disorder (SVD), cerebral 
autosomal dominant 
arteriopathy with subcortical 
infarcts and 
leucoencephalopathy 
(CADASIL) 
Stroke events; cognitive decline; 
focal neurological signs; gait 
disturbance 
SVD: Punctuate and peripheral white 
matter lesions, sparing U-fibers; 
symmetrical and confluent, periventricular 
lesions; lacunar infarcts; involvement of 
central transverse fibres in the pons; 
microbleeds. 
CADASIL: Temporal pole lesions; external 
capsule and U-fibers lesions; microbleeds. 
Serum testing for vascular 
risk factors (diabetes, 
hypercholesterolemia) 
Susac’s syndrome Visual loss; sensorineural hearing 
loss; encephalopathy; headache; 
memory loss; behavioural 
disturbances 
Focal and small lesions in supra and 
infratentorial regions (both white matter 
and grey matter); involvement of corpus 
callosum (snow ball lesions); 
leptomeningeal enhancement;  
 
Fabry disease Stroke events; vertigo Posterior infarcts; multiple white matter 
lesions with pulvinar involvement (T1 
hypointense lesions) 
Reduced activity of the 
alpha-galactosidase 
enzyme; analysis of GLA 
gene 
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Table 3. A summary of the approximate efficacy of the approved DMTs on relapse rate, new MRI lesions, disability progression and 
brain atrophy when compared with placebo.  
 
DMTs Reduction 
in 
relapses 
Reduction 
in new MRI 
lesions 
Reduction 
in disability 
progression  
Reduction in 
whole brain 
atrophy 
 
Alemtuzumab127–129 
 
75% 95% 42% 42% 
Interferons beta 
 
30% 50-70% n.s. n.s. 
Cladribine101,130 
 
55-58% 73-77% 33% 16% 
Daclizumab131 
 
45%* 54%* n.s. n.s. 
Dimethyl fumarate132,133 
 
51% 60% 38% 30% 
Fingolimod134,135 
 
52% 75% 18% 35% 
Glatiramer Acetate 
 
30% 30% n.s. n.s. 
Natalizumab136,137 
 
68% 83% 42% 44% 
Ocrelizumab97 
 
46%* 77-83%* 40%* 23% 
Teriflunomide138,139 
 
30% 50% 30% 25% 
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* compared to interferon-beta 
 
Table 4. Symptomatic management in MS 
 
 
Symptoms 
 
 
Pharmacological treatment 
 
Non-pharmacological 
treatment 
Spasticity For generalised spasticity: 
 
1st line: Baclofen; Tizanidine; Gabapentin (especially for associated spasms);  
 
2nd line: Dantrolene; Diazepam and Clonazepam (at night);  
 
3rd line: add THC:CBD 
 
4th line: Baclofen pump; phenol injections 
 
If focal spasticity: 
 
Botulin toxin injections; phenol injections 
 
Exercise; 
physiotherapy; 
hydrotherapy 
Fatigue Amantadine; modafinil and fampridine (not approved for MS fatigue) Exercise; cognitive 
behavioural therapy; 
occupational therapy; 
energy conservation 
management and 
aerobic training 
 
Impaired 
ambulation 
Fampridine (patients with poor initial drug responses may show a response after long-term 
treatment140 
 
Exercise; 
physiotherapy 
 
Ataxia and 
tremor 
Propanolol; clonazepam; levetiracetam; isoniazid (limited by side effects); botulin toxin injections if 
focal, limb tremor141  
Physiotherapy; surgical 
interventions in 
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 selected cases142  
Bladder 
dysfunction  
For overactive bladder:  
 
Oxybutynin; tolterodine; solifenacin; desmopressin spray (if nocturia); botulin toxin A intra-vesical 
injection; cannabinoids143  
Tibial nerve stimulation 
and sacral 
neuromodulation (as an 
alternative to botulinum 
toxin A, when anti-
muscarinic treatment is 
not effective or 
tolerated);144 
intermittent self-
catheterisations; 
indwelling and 
suprapubic catheter (if 
difficulty in emptying); 
surgical interventions (if 
conservative measures 
fail) 
 
Sexual 
dysfunction 
 
1st line: Sildenafil 
 
2nd line: Intraurethral alprostadil 
 
Cognitive and 
behavioural therapy (if 
underlying depression); 
pelvic floor 
physiotherapy (alone or 
combined with electro-
stimulation or 
transcutaneous tibial 
nerve stimulation) (for 
female sexual 
dysfunction) 145 
 
Bowel 
dysfunction 
 
For constipation: 
 
Laxatives; rectal stimulants (suppositories, enemas); transanal irrigation 
 
For constipation:  
 
Assessment by 
continence 
advisor/physiotherapist; 
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Increase level of 
exercise, abdominal 
massage; biofeedback 
retraining 
 
For incontinence:  
 
Physiotherapy of pelvic 
floor; biofeedback 
retraining; 
enemas/rectal irrigation 
(when incontinence is 
caused by faecal 
impaction); surgery: 
sphincteroplasty, sacral 
nerve stimulation, tibial 
nerve stimulation, 
injectable bulking 
agents, endoscopic 
heat therapy, artificial 
sphincter, colostomy 
 
Depression 
and 
emotional 
lability 
Amitriptyline; antidepressants; dextromethorphan and quinidine for bulbar symptoms 
 
Cognitive and 
behavioural therapy 
(for depression) 
Cognitive 
impairment 
Memantine (although not confirmed by recent randomised trial)146 
 
Cognitive rehabilitation; 
behavioural 
interventions; 
occupational therapy; 
Visual 
problems 
(oscillopsia) 
1st line: Gabapentin 
 
2nd line: Memantine 
 
 
Pain  For neuropathic pain:  Physiotherapy; surgical 
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1st line: Amitriptyline; Duloxetine; Gabapentin; Pregabalin  
 
2nd line: Tramadol; Capsaicin cream (if localised)  
 
For trigeminal neuralgia:  
 
1st line: Carbamazepine 
 
2nd line: Oxcarbazepine, Lamotrigine, Gabapentin, Pregabalin, Baclofen 
 
For Musculoskeletal pain:  
 
Common analgesia; Baclofen (if spasticity) 
 
procedures for 
trigeminal neuralgia 
 
Note: The evidence from this Table comes from the AAN guidelines147, NICE guidelines148, consensus papers149, clinical trial data, previous 
reviews150, and our own opinion.  
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Figures Legend 
Figure 1. Atlas of MS. 
Figure 2. Genetics. The history of genetic discoveries in MS is depicted as a series of images. In each panel, MS is at the center and the 
associated loci are shown as triangles with direct edges or connections.  The concentric circles denote the strength of associations in terms of 
odds of the ratios (OR; a measure of genetic effect size). 
Figure 3. Immunology. Model for the Interaction between immune system and CNS in MS. Activated T and B cells infiltrate the CNS most 
likely attracted by autoantigens expressed in the myelin sheets or the oligodendrocyte. These cells recruit macrophages and activate microglia 
which mediate tissue damage. As a result antigens are released and drained to the periphery (e.g. cervical or paraspinal lymph nodes) where 
they are taken up by antigen presenting cells. This will further activate autoreactive T and B cells which will egress from the lymph node and 
invade the CNS.    
Figure 4. Pathogenic mechanisms of MS and their imaging targets. Inflammation is generally studied by counting gadolinium-enhancing 
areas on T1-images. Neuroaxonal degeneration is measured by determining whole brain atrophy and compartment-specific atrophy (e.g. white, 
grey and deep grey matter). Demyelination is quantified with MTR. Microstructural changes within neurons and axons are measured with DWI, 
ODI and NDI. Specific molecular and metabolic targets for astrocyte activation, neuro-axonal degeneration, microglia activation, energy failure, 
glutamate excitotoxicity and demyelination have been developed on MRS and PET. Sodium imaging quantifies intra- and extra-cellular sodium 
content, and the subsequent ionic imbalance. (MRS: magnetic resonance spectroscopy; PET: positron emission tomography; DWI: diffusion-
weighted imaging; AD: axial diffusivity; FA: fractional anisotropy; ODI: orientation dispersion index; NDI: neurite density index; GABA: Gamma-
Aminobutyric acid; Chol: choline-containing compounds; TSPO: translocator protein; NAA: N-Acetyl-aspartate; Cr: creatine; Pcr: 
phosphocreatine; Glu: glutamate; Gln: glutamine; Gd: Gadolinium; MTR: magnetization transfer imaging; RD: radial diffusivity). 
Figure 5. Phenotypes. This scheme illustrates the relationship between lesions on MRI with clinical signs, and clinical phenotypes. (A) 
Radiologically Isolated Syndrome (RIS) and Clinically Isolated Syndrome (CIS) are characterised by the presence of inflammatory 
demyelinating lesions, without or with associated clinical symptoms/signs. CIS and RRMS can be further defined on the basis of the 
presence/absence of clinical (relapses) and MRI (new/enlarging T2 and gadolinium-enhanced lesions) activity. (B) Progressive MS can be 
defined on the basis of the presence/absence of clinical and MRI (brain atrophy) progression. 
Figure 6. Disease-modifying treatments in MS with their year of discovery/licensing.  
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